Drugs / H1299 Cell Lysates
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05642195 | Jul 2026 → Dec 2033 | non-small cell lung carcinoma | National Cancer Institute (NCI) | Suspended | No outcome recorded |
| Phase 1/2 | NCT02054104 | Sep 2014 → Jun 2015 | melanoma, respiratory system cancer, sarcoma, thoracic cancer | National Cancer Institute (NCI) | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | H1299 Cell Lysates | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05642195 ↗ |
| Modality | Vaccine | “H1299 lung cancer cell lysates (10 mg protein/vaccine) with Iscomatrix™ adjuvant via deep intradermal injection q 4 weeks ×6” PMID 34430349 ↗ Jul 2021 |
| Route | Subcutaneous | “H1299 cell lysate with iscomatrix adjuvant vaccine via subcutaneous injections once every cycle (cycle=28 days) for 6 cycles total.” NCT02054104 ↗ |